Scientists have created a lifelike model of Amyotrophic Lateral Sclerosis (ALS), a type of motor neuron disease, using cells ...

This year's ALS Nexus conference allowed the community to connect with each other, celebrate recent advances, and share hope ...

MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...

A compound normally associated with red blood cells may also play a game-changing antioxidant role in the brain, a study has ...

Adults with SBMA have elevated levels of NfL and GFAP, two biomarkers for nerve damage, in their cerebrospinal fluid, a study ...

New research has shown how hemoglobin acts as an antioxidant in brain cells, forming a target for neurodegenerative disease ...

Familial amyotrophic lateral sclerosis (ALS) is an uncommon form of ALS that occurs due to an inherited gene. The disease causes motor neurons to die, which can lead to progressive muscle weakness.

Amyotrophic Lateral Sclerosis or ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS typically causes muscle atrophy, difficulty in breathing ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.